Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals (Nasdaq: SUPN) has successfully completed the acquisition of the CNS portfolio from US WorldMeds, enhancing its position in treating CNS diseases, specifically Parkinson's disease. This move seeks to diversify revenue streams and strengthen its market presence. CEO Jack Khattar emphasized the acquisition's strategic importance to expand their business. Supernus continues developing various products for CNS conditions, aiming to improve its financial performance while maintaining a robust balance sheet.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced that its management will present an overview and update during the Jefferies Virtual Healthcare Conference on June 2, 2020, at 4:00 p.m. ET. Investors can arrange virtual meetings with management by contacting the conference coordinator. A live webcast of the presentation will be accessible on the company’s website, with a replay available for 60 days post-conference. Supernus focuses on CNS diseases and markets Trokendi XR® and Oxtellar XR® while developing products for ADHD, treatment-resistant depression, and epilepsy.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced receipt of a Paragraph IV Notice Letter from Apotex regarding an Abbreviated New Drug Application for oxcarbazepine extended-release tablets. The company plans to defend its intellectual property rights proactively, having successfully defended Oxtellar XR against previous generic challengers, Actavis and Twi Pharmaceuticals. Currently, Oxtellar XR is protected by nine patents expiring no sooner than 2027. Supernus continues to develop products targeting central nervous system diseases, including candidates for ADHD and treatment-resistant depression.
Supernus Pharmaceuticals reported its Q1 2020 financial results, achieving $95.0 million in total revenue, an 11% increase over 2019. Net product sales were $92.5 million, also rising by 11%. Operating earnings increased to $29.0 million, a 14% increase year-over-year. The company is on track for the launch of SPN-812 pending FDA approval, with a PDUFA date set for November 8, 2020. Additionally, the acquisition of the CNS portfolio from US WorldMeds is expected to close in Q2 2020, enhancing its neurology portfolio and diversifying revenues.
Summary not available.